These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32757299)

  • 21. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.
    Francillon A; Pickering G; Belorgey C
    Therapie; 2009; 64(3):149-59. PubMed ID: 19671427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality.
    Kothare PA; Jadhav PR; Gupta P; Harrelson JC; Dickmann L
    Clin Pharmacol Ther; 2018 Dec; 104(6):1125-1135. PubMed ID: 29696625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclinical Safety Considerations for the Development of Pediatric-First Drugs: An Industry View.
    Schmitt G; Ridings J; De Schaepdrijver L; van Doesum-Wolters FLC; Cappon GD; Hartmann A
    Ther Innov Regul Sci; 2016 Sep; 50(5):632-638. PubMed ID: 30231752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.
    Zane P; Gieschen H; Kersten E; Mathias N; Ollier C; Johansson P; Van den Bergh A; Van Hemelryck S; Reichel A; Rotgeri A; Schäfer K; Müllertz A; Langguth P
    Eur J Pharm Biopharm; 2019 Sep; 142():222-231. PubMed ID: 31233862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application and Impact of Human Dose Projection from Discovery to Early Drug Development.
    Patel D; Yang W; Lipert M; Wu T
    AAPS PharmSciTech; 2020 Jan; 21(2):44. PubMed ID: 31897807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.
    Johnson TN; Small BG; Berglund EG; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Industry embraces virtual trial platforms.
    Dolgin E
    Nat Rev Drug Discov; 2018 Apr; 17(5):305-306. PubMed ID: 29700498
    [No Abstract]   [Full Text] [Related]  

  • 31. Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials.
    Bercu JP; Dolan DG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):162-7. PubMed ID: 22732128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial design: are new methodologies being put into practice?
    Dent SF; Eisenhauer EA
    Ann Oncol; 1996 Aug; 7(6):561-6. PubMed ID: 8879368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of agile designs in first-in-human (FIH) trials--a simulation study.
    Perlstein I; Bolognese JA; Krishna R; Wagner JA
    AAPS J; 2009 Dec; 11(4):653-63. PubMed ID: 19763840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.
    Matthews EJ; Kruhlak NL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Jan; 1(1):61-76. PubMed ID: 16472220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Conduct Considerations for First-in-Human Trials.
    Shen J; Swift B; Mamelok R; Pine S; Sinclair J; Attar M
    Clin Transl Sci; 2019 Jan; 12(1):6-19. PubMed ID: 30048046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
    Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
    Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.